Dr. Marla Dubinsky discusses the unique, personalized, and integrated care offered for children at the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center in a video posted by Mount Sinai Health System.  

Dr. Dubinsky starts by discussing some unique key points about the inflammatory bowel disease center. “First, it is one of the only centers in the country where we’ve integrated both the onset of IBD (inflammatory bowel disease) in childhood and integrated into adult-onset,” states Dr. Dubinksy. This means that there is one common space where caregivers are able to provide care to patients who are children with IBD, as well as patients who are adults with IBD.

Not only does the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center provide cutting-edge, state-of-the-art IBD care, but they also provide the same care for other pediatric GI programs. Other GI programs include:

  • Celiac program
  • Intestinal rehabilitation program
  • Liver program
  • Aerodigestive program
  • And so much more! 

“We want to take problems that are plaguing children, either acute problems or chronic problems, and bring literally state-of-the-art care to no matter what patient we’re approaching,” states Dr. Dubinksy. 

Whole-Person Approach

Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center program revolves around a whole-person approach. This allows high patient satisfaction scores because patients feel safe in this space and get to build a relationship with the individuals working there.

“We are keeping up with how the care paradigms are changing and we’re packaging it and delivering it to patients as soon as they walk in the door,” states Dr. Dubinksy. 

Dr. Dubinksy has relied on therapeutic drug monitoring during induction through iDose’s calculations, which provide data of when a patient will reach target troughs levels and when they will need to receive their next infusion for optimal outcomes. 

Get Started With iDose

iDose is revolutionizing the way inflammatory-disease patients are treated, improving the effectiveness of Infliximab, and ensuring patients do not develop drug-resistant antibodies too soon into treatment. By providing individualized dosing regimens, iDose reduces the chance of drug failure, helping patients reach and maintain remission while lowering overall healthcare costs. 

To learn more about how iDose can improve your patient outcomes, schedule your demo online today.